^
    Back
    Association details:
    Biomarker:ATF7IP-PDGFRB fusion
    Cancer:Acute Lymphocytic Leukemia
    Drug:imatinib (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, PDGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Exp Hematol
    Title:

    Ph-like ALL-related novel fusion kinase ATF7IP-PDGFRB exhibits high sensitivity to tyrosine kinase inhibitors in murine cells

    Excerpt:
    Importantly, the sensitivity of ATF7IP-PDGFRB-expressing Ba/F3 cells to imatinib is significantly higher than that of BCR–ABL1-transformed Ba/F3 cells, as assessed by the IC 50.
    DOI:
    10.1016/j.exphem.2015.11.009